Anti-I™2C/ BRI3/ BRICD2C monoclonal antibody
Anti-I™2C/ BRI3/ BRICD2C antibody for FACS & in-vivo assay
Go to I™2C/I™2C products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-MP0642-Ab-1/ GM-Tg-hg-MP0642-Ab-2 | Anti-Human I™2C monoclonal antibody | Human |
GM-Tg-rg-MP0642-Ab-1/ GM-Tg-rg-MP0642-Ab-2 | Anti-Rat I™2C monoclonal antibody | Rat |
GM-Tg-mg-MP0642-Ab-1/ GM-Tg-mg-MP0642-Ab-2 | Anti-Mouse I™2C monoclonal antibody | Mouse |
GM-Tg-cynog-MP0642-Ab-1/ GM-Tg-cynog-MP0642-Ab-2 | Anti-Cynomolgus/ Rhesus macaque I™2C monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-MP0642-Ab-1/ GM-Tg-felg-MP0642-Ab-2 | Anti-Feline I™2C monoclonal antibody | Feline |
GM-Tg-cang-MP0642-Ab-1/ GM-Tg-cang-MP0642-Ab-2 | Anti-Canine I™2C monoclonal antibody | Canine |
GM-Tg-bovg-MP0642-Ab-1/ GM-Tg-bovg-MP0642-Ab-2 | Anti-Bovine I™2C monoclonal antibody | Bovine |
GM-Tg-equg-MP0642-Ab-1/ GM-Tg-equg-MP0642-Ab-2 | Anti-Equine I™2C monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-MP0642-Ab-1/ GM-Tg-hg-MP0642-Ab-2; GM-Tg-rg-MP0642-Ab-1/ GM-Tg-rg-MP0642-Ab-2; GM-Tg-mg-MP0642-Ab-1/ GM-Tg-mg-MP0642-Ab-2; GM-Tg-cynog-MP0642-Ab-1/ GM-Tg-cynog-MP0642-Ab-2; GM-Tg-felg-MP0642-Ab-1/ GM-Tg-felg-MP0642-Ab-2; GM-Tg-cang-MP0642-Ab-1/ GM-Tg-cang-MP0642-Ab-2; GM-Tg-bovg-MP0642-Ab-1/ GM-Tg-bovg-MP0642-Ab-2; GM-Tg-equg-MP0642-Ab-1/ GM-Tg-equg-MP0642-Ab-2 |
Products Name | Anti-I™2C monoclonal antibody |
Format | mab |
Target Name | I™2C |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-I™2C benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species I™2C/ BRI3/ BRICD2C VLP (virus-like particle) (Products Developing) |
ORF Viral Vector | pGMLP004862 | human I™2C Lentivirus plasmid |
ORF Viral Vector | vGMLP004862 | human I™2C Lentivirus particle |
Target information
Target ID | GM-MP0642 |
Target Name | I™2C |
Gene ID | 81618,64294,301575,711245,486156,101090636,539959,100063933 |
Gene Symbol and Synonyms | 3110038L02Rik,BRI3,BRICD2C,E25,E25C,I™2C,I™3 |
Uniprot Accession | Q9NQX7,Q5PQL7,A2VDN0 |
Uniprot Entry Name | I™2C_HUMAN,I™2C_RAT,I™2C_BOVIN |
Protein Sub-location | Transmembrane Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000135916 |
Target Classification | N/A |
The target: I™2C, gene name: I™2C, also named as BRI3, BRICD2C, E25, E25C, I™3. Enables amyloid-beta binding activity. Involved in negative regulation of neuron projection development and neuron differentiation. Located in several cellular components, including Golgi apparatus; lysosome; and perinuclear region of cytoplasm. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.